Medtronic stock enters new phase after MiniMed separation

Published on 10/30/2026 at 10:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Medtronic stock enters a new phase after the MiniMed separation. The exchange offer was 5.4 times oversubscribed.

What MiniMed separation means

Medtronic exchanged all of its remaining shares in the diabetes technology business.
The exchange offer was 5.4 times oversubscribed, supporting the launch of MiniMed as an independent company.
Investors will now assess Medtronic's growth and capital allocation after the diabetes exit.

Medtronic plc, IE00BTN1Y115, Illustration mit AI erstellt.

Medtronic plc has completed the separation of its MiniMed diabetes technology business, closing a portfolio transaction that had been in focus for investors throughout October. The company announced the completion on October 15, 2026, according to the Ground News page carrying the PR Newswire release.

The transaction transferred Medtronic's remaining interest in MiniMed to the exchange-offer participants. The offer was 5.4 times oversubscribed, and the newly issued MiniMed shares were to be credited to tendering shareholders in book-entry form. MiniMed now operates as an independent diabetes technology company under the Nasdaq ticker MMED.

Portfolio shift changes investor focus

The separation removes diabetes technology from Medtronic's continuing portfolio and leaves the medical-device group more concentrated on areas including cardiovascular care, neuroscience and surgical technologies. For investors, the next question is how the company converts that narrower portfolio into sustained organic growth while managing research spending, commercial execution and capital allocation.

The transaction also changes the comparison base for future results. Medtronic's recent fiscal first-quarter performance included revenue of USD 9.76 billion and adjusted earnings per share of USD 1.45, according to the company's recent earnings coverage on its investor theme page. Those figures predate the completed separation and should not be treated as a direct measure of the post-MiniMed company.

Trading remains focused on next catalysts

Medtronic stock traded at 87.07 euros on Lang & Schwarz at 10:32 CEST on Friday, October 30, 2026. The quote was 0.20 euros above the listed previous close of 86.87 euros on the same trading venue, but the article does not use that venue comparison as a Xetra benchmark.

Investors can follow the real-time quote of Medtronic stock as the market evaluates the separation and the company's next operating update. The next major catalyst is the forthcoming fiscal second-quarter report, where investors are likely to focus on revenue growth, adjusted earnings and the outlook for the continuing businesses.